Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Assets: 2010-2024

Historic Other Non-Current Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $614,000.

  • Lineage Cell Therapeutics' Other Non-Current Assets fell 11.06% to $539,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $539,000, marking a year-over-year decrease of 11.06%. This contributed to the annual value of $614,000 for FY2024, which is 6.41% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Other Non-Current Assets stood at $614,000 for FY2024, which was up 6.41% from $577,000 recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Non-Current Assets peaked at $630,000 during FY2021, and registered a low of $577,000 during FY2023.
  • Over the past 3 years, Lineage Cell Therapeutics' median Other Non-Current Assets value was $614,000 (recorded in 2024), while the average stood at $606,000.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Non-Current Assets decreased by 7.97% in 2023 and then climbed by 6.41% in 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Non-Current Assets (Yearly) stood at $616,000 in 2020, then grew by 2.27% to $630,000 in 2021, then fell by 0.48% to $627,000 in 2022, then fell by 7.97% to $577,000 in 2023, then rose by 6.41% to $614,000 in 2024.